vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $19.2M, roughly 2.0× CuriosityStream Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -161.8%, a 142.1% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 35.8%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-71.3M).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

CURI vs IBRX — Head-to-Head

Bigger by revenue
IBRX
IBRX
2.0× larger
IBRX
$38.3M
$19.2M
CURI
Growing faster (revenue YoY)
IBRX
IBRX
+371.1% gap
IBRX
407.0%
35.8%
CURI
Higher net margin
CURI
CURI
142.1% more per $
CURI
-19.7%
-161.8%
IBRX
More free cash flow
CURI
CURI
$75.2M more FCF
CURI
$3.9M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CURI
CURI
IBRX
IBRX
Revenue
$19.2M
$38.3M
Net Profit
$-3.8M
$-61.9M
Gross Margin
99.0%
Operating Margin
-17.6%
-169.0%
Net Margin
-19.7%
-161.8%
Revenue YoY
35.8%
407.0%
Net Profit YoY
-34.6%
-4.7%
EPS (diluted)
$-0.07
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
IBRX
IBRX
Q4 25
$19.2M
$38.3M
Q3 25
$18.4M
$32.1M
Q2 25
$19.0M
$26.4M
Q1 25
$15.1M
$16.5M
Q4 24
$14.1M
$7.6M
Q3 24
$12.6M
$6.1M
Q2 24
$12.4M
Q1 24
$12.0M
Net Profit
CURI
CURI
IBRX
IBRX
Q4 25
$-3.8M
$-61.9M
Q3 25
$-3.7M
$-67.3M
Q2 25
$784.0K
$-92.6M
Q1 25
$319.0K
$-129.6M
Q4 24
$-2.8M
$-59.2M
Q3 24
$-3.1M
$-85.7M
Q2 24
$-2.0M
Q1 24
$-5.0M
Gross Margin
CURI
CURI
IBRX
IBRX
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
CURI
CURI
IBRX
IBRX
Q4 25
-17.6%
-169.0%
Q3 25
-24.5%
-173.5%
Q2 25
2.5%
-269.8%
Q1 25
0.5%
-390.1%
Q4 24
-27.4%
-919.0%
Q3 24
-25.8%
-1314.3%
Q2 24
-20.6%
Q1 24
-30.4%
Net Margin
CURI
CURI
IBRX
IBRX
Q4 25
-19.7%
-161.8%
Q3 25
-20.4%
-209.8%
Q2 25
4.1%
-350.3%
Q1 25
2.1%
-784.9%
Q4 24
-19.9%
-783.4%
Q3 24
-24.3%
-1404.0%
Q2 24
-16.4%
Q1 24
-42.0%
EPS (diluted)
CURI
CURI
IBRX
IBRX
Q4 25
$-0.07
$-0.06
Q3 25
$-0.06
$-0.07
Q2 25
$0.01
$-0.10
Q1 25
$0.01
$-0.15
Q4 24
$-0.05
$-0.08
Q3 24
$-0.06
$-0.14
Q2 24
$-0.04
Q1 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$27.3M
$242.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$41.5M
$-500.5M
Total Assets
$75.7M
$501.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
IBRX
IBRX
Q4 25
$27.3M
$242.8M
Q3 25
$27.8M
$257.8M
Q2 25
$28.1M
$153.7M
Q1 25
$33.4M
$61.6M
Q4 24
$32.1M
$149.8M
Q3 24
$33.2M
$130.4M
Q2 24
$39.5M
Q1 24
$38.8M
Stockholders' Equity
CURI
CURI
IBRX
IBRX
Q4 25
$41.5M
$-500.5M
Q3 25
$47.2M
$-524.3M
Q2 25
$49.8M
$-570.7M
Q1 25
$58.1M
$-591.4M
Q4 24
$57.8M
$-489.1M
Q3 24
$62.2M
$-745.1M
Q2 24
$64.8M
Q1 24
$67.0M
Total Assets
CURI
CURI
IBRX
IBRX
Q4 25
$75.7M
$501.9M
Q3 25
$74.7M
$519.0M
Q2 25
$78.7M
$402.1M
Q1 25
$85.3M
$303.8M
Q4 24
$86.2M
$382.9M
Q3 24
$87.6M
$364.6M
Q2 24
$90.9M
Q1 24
$94.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
IBRX
IBRX
Operating Cash FlowLast quarter
$4.0M
$-70.4M
Free Cash FlowOCF − Capex
$3.9M
$-71.3M
FCF MarginFCF / Revenue
20.5%
-186.2%
Capex IntensityCapex / Revenue
0.1%
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
IBRX
IBRX
Q4 25
$4.0M
$-70.4M
Q3 25
$4.4M
$-68.9M
Q2 25
$2.8M
$-79.7M
Q1 25
$1.9M
$-85.9M
Q4 24
$3.0M
$-85.1M
Q3 24
$2.3M
$-98.8M
Q2 24
$2.2M
Q1 24
$666.0K
Free Cash Flow
CURI
CURI
IBRX
IBRX
Q4 25
$3.9M
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$1.8M
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
Q1 24
FCF Margin
CURI
CURI
IBRX
IBRX
Q4 25
20.5%
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
12.2%
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Q1 24
Capex Intensity
CURI
CURI
IBRX
IBRX
Q4 25
0.1%
2.4%
Q3 25
0.0%
2.3%
Q2 25
0.0%
4.1%
Q1 25
0.5%
6.8%
Q4 24
0.0%
28.0%
Q3 24
0.0%
45.7%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
CURI
CURI
IBRX
IBRX
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons